Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GeparOla: Olaparib vs Carboplatin in HER2-negative HRD Breast Cancer
NCT02789332Phase 2Completed
- Sponsor
- GBG Forschungs
- Start
- Sep 2016
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in breast cancer, sponsored by GBG Forschungs. Started Sep 2016; status: completed.
02
Drugs
olaparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02789332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02789332.